Clinical trials: Six-minute Walk Test
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Pulmonary Arterial Hypertension
Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary hypertension is characterized by an increase in the pressures in the blood supply to the lungs greater than a mean pressure of 25mmHg and a concomitant increase in overall pulmonary vascular resistance (PVR).
- Trial name
- NCT02734953
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Obesity
Cardiometabolic Disease and Pulmonary Hypertension
This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S.
- Trial name
- NCT03349775
- Testing
- Metformin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Sickle Cell Disease
Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of sickle-shaped red blood cells. In the U.S. and the U.K. this occurs primarily in persons of African origin.
- Trial name
- NCT01987908
- Testing
- Aes-103
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Baxalta now part of Shire
Pulmonary Hypertension
Evaluation of a New 6 Minute Walk Test Smartphone App in Patients With Pulmonary Hypertension
Comparison of standard 6 minute walk test with 6 minute walk test smartphone app.
- Trial name
- 6-APP (NCT04633538)
- Testing
- 6MWT smartphone app
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
Oximetry
The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test
The primary aim of this research is to determine the accuracy of smartphone pulse oximeters in detecting blood oxygen saturations, episodes of desaturations, and heart rate by comparing results to a Masimo© hospital-grade pulse…
- Trial name
- NCT03534271
- Testing
- iPhone with Kenek Edge and Samsung S8
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Rush University Medical Center
Heart Failure, Left Ventricular Dysfunction
Effects of Viagra on Heart Function in Patients With Heart Failure
Sildenafil (Viagra) is known to reduce pulmonary hypertension. Heart failure patients also have pulmonary hypertension and several recent reports have shown that sildenafil leads to an improvement in their exercise capacity.
- Trial name
- NCT00781508
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MetroHealth Medical Center
Chronic Obstructive Pulmonary Disease
Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients
The aim of this study is to investigate the six-minute-walking-distance of COPD-patients with breathing oxygen in comparison to breathing normal air.
- Trial name
- NCT00886639
- Testing
- 6MWT with oxygen, 6MWT with medical air
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Hypoxemia, Anoxia
Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation
This trial will test the hypothesis that the 6 minute walk test (6MWT) is not reproducible as a measure for oxygen desaturation.
- Conditions
- Hypoxemia, Anoxia, Chronic Obstructive Pulmonary Disease
- Trial name
- 6MWT (NCT00740220)
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Wake Forest University Health Sciences
Pulmonary Arterial Hypertension
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional…
- Trial name
- VIPAH-PRN_2B (NCT04266197)
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
- Where
- 26 sites in United States
- Volunteers
- 42 people
- Sponsor
- Respira Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction (HFpEF)
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction…
- Trial name
- NCT03877224
- Testing
- Dapagliflozin
- Where
- 101 sites in United States, Argentina and 10 more
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
- Trial name
- FREEDOM-EV (NCT01560624)
- Testing
- Treprostinil Diolamine
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 690 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
- Trial name
- TRUST-2 (NCT03055221)
- Testing
- Intravenous Treprostinil
- Volunteers
- 20 people
- Sponsor
- United Therapeutics
Heart Failure
PRospective Evaluation of Electrocardiographic Voltage Changes and Six Minute Walk Test for Predicting Readmissions in Heart Failure (PREEMT-HF Study)
Purpose of the study: To identify whether Electrocardiographic QRS voltage changes (between admission and pre-discharge) and pre discharge 6- minute walk test in patients admitted with acute heart failure can identify patients at…
- Trial name
- PREEMT-HF (NCT01675544)
- Testing
- Electrocardiogram, Six minute walk test
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Creighton University
Respiratory Disease
Comparing 6-Minute Walk Tests for Ambulatory Oxygen Assessment
Patients with lung disease who report breathlessness on exertion are often referred for a 6MWT. Due to the nature of the 6MWT (hereon referred to as a Max-6MWT), patients are required to walk as far as they can in 6 minutes.
- Trial name
- NCT05630092
- Testing
- Maximal 6-minute Walk Test (Max_6MWT), Normal speed 6-minute Walk Test (Nor_6MWT)
- Where
- United Kingdom
- Volunteers
- 93 people
- Sponsor
- Hampshire Hospitals NHS Foundation Trust
PMV, Exercise Endurance
Does Endurance Improve With the Use of Passy-Muir Valve for Patients With Tracheostomy?
The purpose of this study is to determine if the use of the Passy-Muir Valve improves endurance for patients in the Long Term Acute Care setting as measured with the Six- Minute Walk Test.
- Conditions
- PMV, Exercise Endurance, Tracheostomy
- Trial name
- NCT04941456
- Testing
- Open Tracheostomy, PMV in place
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Gaylord Hospital, Inc
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Cardiac Rehabilitation
The Healthy Heart Study
The long-term goal of this research is to improve patient-centered outcomes in patients with coronary heart disease (CHD), the leading cause of death in the world.
- Trial name
- NCT02105246
- Testing
- Referral to home-based cardiac rehab, Referral to center-based cardiac rehab
- Where
- United States
- Volunteers
- 1,154 people
- Sponsor
- University of California, San Francisco